|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
TW201726656A
(zh)
|
2015-11-16 |
2017-08-01 |
亞瑞克西斯製藥公司 |
包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
|
|
KR102444509B1
(ko)
|
2016-05-18 |
2022-09-19 |
미라티 테라퓨틱스, 인크. |
Kras g12c 억제제
|
|
EP3824906A1
(en)
|
2016-12-21 |
2021-05-26 |
Amgen Inc. |
Anti-tnf alpha antibody formulations
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
TW201900633A
(zh)
|
2017-05-25 |
2019-01-01 |
美商亞瑞克西斯製藥公司 |
Kras之共價抑制劑
|
|
JP2020521740A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
|
|
WO2018218071A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
|
EA202091186A1
(ru)
|
2017-11-15 |
2020-10-01 |
Мирати Терапьютикс, Инк. |
ИНГИБИТОРЫ KRas G12C
|
|
US10647715B2
(en)
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
US11932633B2
(en)
|
2018-05-07 |
2024-03-19 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
JP2021176819A
(ja)
*
|
2018-07-31 |
2021-11-11 |
アステラス製薬株式会社 |
キナゾリン化合物を有効成分とする医薬組成物
|
|
JP2021176820A
(ja)
*
|
2018-07-31 |
2021-11-11 |
アステラス製薬株式会社 |
キナゾリン化合物を有効成分とする医薬組成物
|
|
US12134620B2
(en)
|
2018-08-01 |
2024-11-05 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
PT3849537T
(pt)
|
2018-09-10 |
2025-01-22 |
Mirati Therapeutics Inc |
Terapêuticas de combinação
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
JP2022500385A
(ja)
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス， インコーポレイテッド |
組み合わせ療法
|
|
KR20210083286A
(ko)
*
|
2018-10-24 |
2021-07-06 |
아락세스 파마 엘엘씨 |
종양 전이를 억제하기 위한 g12c 돌연변이 kras 단백질의 억제제로서 2-(2-아크릴로일-2,6-디아자스피로[3.4]옥탄-6-일)-6-(1h-인다졸-4-일)-벤조니트릴 유도체 및 관련 화합물
|
|
WO2020085493A1
(ja)
*
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
新規なインダゾール化合物又はその塩
|
|
AU2019388998A1
(en)
*
|
2018-11-29 |
2021-06-03 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
|
CA3112129A1
(en)
|
2018-12-05 |
2020-06-11 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3908283A4
(en)
*
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
CN111499634B
(zh)
*
|
2019-01-31 |
2023-05-12 |
贝达药业股份有限公司 |
一种喹唑啉化合物及其在医药上的应用
|
|
CN113382774A
(zh)
|
2019-02-12 |
2021-09-10 |
诺华股份有限公司 |
包含tno155和krasg12c抑制剂的药物组合
|
|
WO2020177629A1
(zh)
*
|
2019-03-01 |
2020-09-10 |
劲方医药科技(上海)有限公司 |
螺环取代的嘧啶并环类化合物，其制法与医药上的用途
|
|
EP3935060B1
(en)
|
2019-03-05 |
2023-11-15 |
Astrazeneca AB |
Fused tricyclic compounds useful as anticancer agents
|
|
WO2020207483A1
(zh)
*
|
2019-04-10 |
2020-10-15 |
南京明德新药研发有限公司 |
一种egfr抑制剂的晶型及其制备方法
|
|
KR20220012248A
(ko)
*
|
2019-04-22 |
2022-02-03 |
베타 파머수티컬 컴퍼니 리미티드 |
퀴나졸린 화합물 및 이의 의약품에서의 응용
|
|
AU2020279253A1
(en)
*
|
2019-05-20 |
2021-12-16 |
1200 Pharma Llc |
KRAS G12C inhibitors and uses thereof
|
|
CN112110918B
(zh)
*
|
2019-06-21 |
2023-08-22 |
劲方医药科技(上海)有限公司 |
螺环取代的嘧啶并环类化合物，其制法与医药上的用途
|
|
US12421236B2
(en)
|
2019-06-25 |
2025-09-23 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
|
|
WO2021031952A1
(zh)
*
|
2019-08-16 |
2021-02-25 |
劲方医药科技(上海)有限公司 |
氧代六元环并嘧啶类化合物，其制法与医药上的用途
|
|
KR20220071193A
(ko)
|
2019-08-29 |
2022-05-31 |
미라티 테라퓨틱스, 인크. |
Kras g12d 억제제
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
US11890285B2
(en)
|
2019-09-24 |
2024-02-06 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
UA129778C2
(uk)
|
2019-10-28 |
2025-07-30 |
Мерк Шарп Енд Доум Елелсі |
Низькомолекулярні інгібітори g12c-мутантного kras
|
|
AU2020379731A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CA3159561A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN112851663B
(zh)
*
|
2019-11-12 |
2023-07-18 |
博瑞生物医药（苏州）股份有限公司 |
一种并杂环化合物及其用途
|
|
WO2021093758A1
(zh)
*
|
2019-11-15 |
2021-05-20 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
US12479834B2
(en)
|
2019-11-29 |
2025-11-25 |
Taiho Pharmaceutical Co., Ltd. |
Phenol compound or salt thereof
|
|
WO2021106231A1
(en)
*
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
CN115135315B
(zh)
|
2019-12-20 |
2024-11-26 |
米拉蒂治疗股份有限公司 |
Sos1抑制剂
|
|
US12479843B2
(en)
|
2019-12-27 |
2025-11-25 |
Soochow University |
Spiro ring-containing quinazoline compounds
|
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
TW202140450A
(zh)
*
|
2020-02-24 |
2021-11-01 |
大陸商泰勵生物科技（上海）有限公司 |
用於癌症治療的ｋｒａｓ抑制劑
|
|
EP4112606A4
(en)
*
|
2020-02-24 |
2024-04-10 |
Shanghai Zheye Biotechnology Co., Ltd. |
AROMATIC COMPOUND AND ITS USE IN THE PREPARATION OF ANTINEOPLASIC DRUGS
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
CN115335379B
(zh)
*
|
2020-03-25 |
2024-03-29 |
微境生物医药科技(上海)有限公司 |
含螺环的喹唑啉化合物
|
|
TW202214654A
(zh)
*
|
2020-06-10 |
2022-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合喹唑啉類衍生物、其製備方法及其在醫藥上的應用
|
|
TW202214253A
(zh)
|
2020-06-18 |
2022-04-16 |
美商銳新醫藥公司 |
延遲、預防及治療對ｒａｓ抑制劑之後天抗性之方法
|
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
MX2023002942A
(es)
|
2020-09-11 |
2023-05-22 |
Mirati Therapeutics Inc |
Formas cristalinas de un inhibidor de kras g12c.
|
|
PE20231207A1
(es)
|
2020-09-15 |
2023-08-17 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer
|
|
WO2022063297A1
(zh)
*
|
2020-09-27 |
2022-03-31 |
微境生物医药科技(上海)有限公司 |
喹唑啉衍生物及其制备方法和用途
|
|
EP4223761A4
(en)
*
|
2020-09-30 |
2025-03-12 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
QUINAZOLINE COMPOUND AND ITS APPLICATION
|
|
WO2022083616A1
(zh)
*
|
2020-10-21 |
2022-04-28 |
贝达药业股份有限公司 |
一种喹唑啉化合物及其药物组合物
|
|
CN112341351B
(zh)
*
|
2020-10-27 |
2022-03-11 |
无锡双启科技有限公司 |
一种2-氨基-4-溴-3-氟-5-碘苯甲酰胺的制备方法
|
|
WO2022105855A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
CN115803328B
(zh)
*
|
2020-11-24 |
2024-07-23 |
成都百裕制药股份有限公司 |
哌嗪-2,3-二酮衍生物及其在医药上的应用
|
|
CA3198885A1
(en)
|
2020-12-15 |
2022-06-23 |
Xiaolun Wang |
Azaquinazoline pan-kras inhibitors
|
|
US11999753B2
(en)
|
2020-12-16 |
2024-06-04 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-KRas inhibitors
|
|
US20240100172A1
(en)
|
2020-12-21 |
2024-03-28 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
WO2022135470A1
(zh)
*
|
2020-12-22 |
2022-06-30 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
|
WO2022135390A1
(zh)
*
|
2020-12-25 |
2022-06-30 |
四川海思科制药有限公司 |
己酮糖激酶抑制剂及其用途
|
|
WO2022152313A1
(zh)
*
|
2021-01-18 |
2022-07-21 |
成都百裕制药股份有限公司 |
嘧啶衍生物及其在医药上的应用
|
|
WO2022171135A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
微境生物医药科技(上海)有限公司 |
含螺环的喹唑啉衍生物
|
|
WO2022171147A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
嘧啶并芳香环类化合物
|
|
WO2022173870A1
(en)
*
|
2021-02-09 |
2022-08-18 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
CN116848120A
(zh)
*
|
2021-02-15 |
2023-10-03 |
安斯泰来制药株式会社 |
用于诱导g12d突变kras蛋白分解的喹唑啉化合物
|
|
CA3211110A1
(en)
*
|
2021-02-15 |
2022-08-18 |
Astellas Pharma Inc. |
4-aminoquinazoline compound
|
|
CN115124524A
(zh)
*
|
2021-03-26 |
2022-09-30 |
浙江海正药业股份有限公司 |
三环类衍生物及其制备方法和用途
|
|
WO2022232318A1
(en)
*
|
2021-04-27 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
MX2023013085A
(es)
|
2021-05-05 |
2023-11-16 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
|
US20240300980A1
(en)
*
|
2021-05-22 |
2024-09-12 |
Shanghai Kechow Pharma, Inc. |
Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment
|
|
CA3217694A1
(en)
*
|
2021-05-24 |
2022-12-01 |
Zusheng XU |
Nitrogen-containing heterocyclic compound, method for preparing same and use of same
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
KR20240041917A
(ko)
|
2021-07-27 |
2024-04-01 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
|
WO2023031781A1
(en)
|
2021-09-01 |
2023-03-09 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
EP4389751A1
(en)
|
2021-09-03 |
2024-06-26 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
CN117222646A
(zh)
*
|
2021-09-16 |
2023-12-12 |
苏州赞荣医药科技有限公司 |
Kras g12c抑制剂和其用途
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
|
WO2023122723A1
(en)
|
2021-12-23 |
2023-06-29 |
The Broad Institute, Inc. |
Panels and methods for diagnosing and treating lung cancer
|
|
WO2023119677A1
(en)
*
|
2021-12-24 |
2023-06-29 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising a quinazoline compound
|
|
CR20240347A
(es)
*
|
2022-01-21 |
2025-02-17 |
Usynova Pharmaceuticals Ltd |
Compuestos de benzopirimidina y uso de estos
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
TW202346270A
(zh)
*
|
2022-03-11 |
2023-12-01 |
日商安斯泰來製藥股份有限公司 |
用於誘發g12d突變kras蛋白分解之雜環化合物
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
CN120504682A
(zh)
|
2022-06-10 |
2025-08-19 |
锐新医药公司 |
大环ras抑制剂
|
|
EP4567033A1
(en)
*
|
2022-08-05 |
2025-06-11 |
Astellas Pharma Inc. |
Heterocyclic compound for inducing degradation of mutant kras protein
|
|
TW202413346A
(zh)
*
|
2022-08-09 |
2024-04-01 |
日商安斯泰來製藥股份有限公司 |
用於誘導g12v突變kras蛋白之分解之雜環化合物
|
|
TW202412790A
(zh)
|
2022-08-09 |
2024-04-01 |
日商安斯泰來製藥股份有限公司 |
用於抑制及/或誘導分解kras蛋白之雜環化合物
|
|
WO2024034123A1
(ja)
*
|
2022-08-12 |
2024-02-15 |
アステラス製薬株式会社 |
複素環化合物を含む医薬組成物
|
|
IL318758A
(en)
*
|
2022-08-12 |
2025-04-01 |
Astellas Pharma Inc |
Anti-cancer combinations containing chemotherapy
|
|
KR20250044876A
(ko)
|
2022-08-12 |
2025-04-01 |
아스텔라스세이야쿠 가부시키가이샤 |
G12d 돌연변이체 kras 억제 활성을 갖는 이관능성 화합물을 포함하는 항암제의 조합물
|
|
GB202212641D0
(en)
|
2022-08-31 |
2022-10-12 |
Jazz Pharmaceuticals Ireland Ltd |
Novel compounds
|
|
IL320639A
(en)
|
2022-11-09 |
2025-07-01 |
Revolution Medicines Inc |
Compounds, complexes and methods for their preparation and use
|
|
WO2024188281A1
(zh)
*
|
2023-03-13 |
2024-09-19 |
南京明德新药研发有限公司 |
含喹唑啉结构的化合物及其应用
|
|
KR20250164828A
(ko)
|
2023-03-30 |
2025-11-25 |
레볼루션 메디슨즈, 인크. |
Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
AU2024253668A1
(en)
|
2023-04-07 |
2025-11-13 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
US20240352038A1
(en)
|
2023-04-14 |
2024-10-24 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
WO2024243441A1
(en)
|
2023-05-24 |
2024-11-28 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2025007000A1
(en)
|
2023-06-30 |
2025-01-02 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
|
WO2025052649A1
(ja)
*
|
2023-09-08 |
2025-03-13 |
アステラス製薬株式会社 |
単一の軸不斉化合物の選択的製造法
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202535891A
(zh)
|
2023-10-20 |
2025-09-16 |
美商默沙東有限責任公司 |
Ｋｒａｓ蛋白之小分子抑制劑
|
|
WO2025171055A1
(en)
|
2024-02-06 |
2025-08-14 |
Kumquat Biosciences Inc. |
Heterocyclic conjugates and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025230971A1
(en)
|
2024-04-30 |
2025-11-06 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles as anticancer agents
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|